SWEDISH ORPHAN BIOVITRUM AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 1.7K
- Market Cap
- -
- Website
- http://www.sobi.com
Clinical Trials
10
Active:9
Completed:1
Trial Phases
2 Phases
Phase 1:7
Phase 3:1
Drug Approvals
1
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (87.5%)Phase 3
1 (12.5%)No trials found
News
ViroGates and Sobi Expand Collaboration on suPARnostic® Diagnostic for Kineret® Treatment
ViroGates has amended its agreement with Sobi to expand development of suPARnostic® TurbiLatex for use with Kineret® (anakinra) in the US market and to support EU regulatory compliance.
UK MHRA Approves Sobi's Efanesoctocog Alfa for Haemophilia A Treatment
The UK Medicines and Healthcare products Regulatory Agency has approved efanesoctocog alfa (Altuvoct) for treating and preventing bleeding in patients aged 2 years and above with severe or moderate haemophilia A.